Targeted Therapy in Pediatric Langerhans Cell Histiocytosis: Describing a Novel Strategy to Minimize Long‐Term Exposure While Maintaining Efficacy
Pediatric Blood & Cancer · 2025
DOI: 10.1002/pbc.32016 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Natalia Wojciechowska und 6 weiteren Autor:innen. Beteiligte Einrichtung: Cook Children's Medical Center, Fort Worth, Texas, USA. Hauptthemen laut MEDLINE: Histiocytosis, Langerhans-Cell, Pyridones, Pyrimidinones, Molecular Targeted Therapy. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
Background
Langerhans cell histiocytosis (LCH) is a rare malignancy driven by MAPK pathway activation and often involves BRAF V600E mutations. Targeted therapy with trametinib, a MEK inhibitor, is a promising alternative to conventional chemotherapy. Procedure We retrospectively analyzed the records of patients treated with trametinib either at relapse or as front‐line therapy between 2020 and 2024.
Results
Fifteen pediatric patients received trametinib either at diagnosis ( n = 6), relapse ( n = 7), or due to chemotherapy intolerance ( n = 2). Molecular testing identified MAPK pathway mutations in 11 patients. The median age at treatment initiation was 5 years (range: 0.1–16.5). Notably, five of these patients started trametinib before the age of 1. The median treatment duration was 2.2 years (range: 0.1–4.7 years). All 15 patients achieved favorable responses without concerns regarding growth and development. The adverse effects included rash (40%) and diarrhea (13%), which were all mild and were managed with temporary dose adjustments. A self‐weaning dosing strategy minimized long‐term exposure while maintaining disease control.
Conclusion
Our data suggest that trametinib is a safe and effective therapy for pediatric LCH with broad efficacy and tolerability. However, prospective studies are needed to confirm these findings and refine targeted treatment protocols.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cook Children's Medical Center, Fort Worth, Texas, USA.
- Anne Burnett Marion School of Medicine at TCU, Fort Worth, Texas, USA.
ORCID-Profile: Natalia Wojciechowska, Alexandra E Richards, Kelly Vallance, Anish Ray
Zitieren
APA
Wojciechowska, N., Richards, A. E., Anthony, A., Diaz, M., Vallance, K., Greer, C., & Ray, A. (2025). Targeted Therapy in Pediatric Langerhans Cell Histiocytosis: Describing a Novel Strategy to Minimize Long‐Term Exposure While Maintaining Efficacy. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.32016
Vancouver
Wojciechowska N, Richards AE, Anthony A, Diaz M, Vallance K, Greer C, et al. Targeted Therapy in Pediatric Langerhans Cell Histiocytosis: Describing a Novel Strategy to Minimize Long‐Term Exposure While Maintaining Efficacy. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.32016
BibTeX
@article{Wojciechowska2025,
author = {Wojciechowska, Natalia and Richards, Alexandra E and Anthony, Aly and Diaz, Maranda and Vallance, Kelly and Greer, Chelsee and Ray, Anish},
title = {Targeted Therapy in Pediatric Langerhans Cell Histiocytosis: Describing a Novel Strategy to Minimize Long‐Term Exposure While Maintaining Efficacy},
journal = {Pediatric Blood & Cancer},
year = {2025},
doi = {10.1002/pbc.32016}
}
EUVIMED